A modified Sequential Organ Failure Assessment score for dengue: development, evaluation and proposal for use in clinical trials
-
Published:2022-09-03
Issue:1
Volume:22
Page:
-
ISSN:1471-2334
-
Container-title:BMC Infectious Diseases
-
language:en
-
Short-container-title:BMC Infect Dis
Author:
McBride Angela,Vuong Nguyen Lam,Van Hao Nguyen,Huy Nguyen Quang,Chanh Ho Quang,Chau Nguyen Thi Xuan,Nguyet Nguyen Minh,Ming Damien K.,Ngoc Nguyen Thanh,Nhat Phung Tran Huy,Phong Nguyen Thanh,Tai Luong Thi Hue,Tho Phan Vinh,Trung Dinh The,Tam Dong Thi Hoai,Trieu Huynh Trung,Geskus Ronald Bertus,Llewelyn Martin J.,Thwaites C. Louise,Yacoub Sophie
Abstract
Abstract
Background
Dengue is a neglected tropical disease, for which no therapeutic agents have shown clinical efficacy to date. Clinical trials have used strikingly variable clinical endpoints, which hampers reproducibility and comparability of findings. We investigated a delta modified Sequential Organ Failure Assessment (delta mSOFA) score as a uniform composite clinical endpoint for use in clinical trials investigating therapeutics for moderate and severe dengue.
Methods
We developed a modified SOFA score for dengue, measured and evaluated its performance at baseline and 48 h after enrolment in a prospective observational cohort of 124 adults admitted to a tertiary referral hospital in Vietnam with dengue shock. The modified SOFA score included pulse pressure in the cardiovascular component. Binary logistic regression, cox proportional hazard and linear regression models were used to estimate association between mSOFA, delta mSOFA and clinical outcomes.
Results
The analysis included 124 adults with dengue shock. 29 (23.4%) patients required ICU admission for organ support or due to persistent haemodynamic instability: 9/124 (7.3%) required mechanical ventilation, 8/124 (6.5%) required vasopressors, 6/124 (4.8%) required haemofiltration and 5/124 (4.0%) patients died. In univariate analyses, higher baseline and delta (48 h) mSOFA score for dengue were associated with admission to ICU, requirement for organ support and mortality, duration of ICU and hospital admission and IV fluid use.
Conclusions
The baseline and delta mSOFA scores for dengue performed well to discriminate patients with dengue shock by clinical outcomes, including duration of ICU and hospital admission, requirement for organ support and death. We plan to use delta mSOFA as the primary endpoint in an upcoming host-directed therapeutic trial and investigate the performance of this score in other phenotypes of severe dengue in adults and children.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases
Reference39 articles.
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. 2. Geneva: World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. Geneva; 2009. 1–144pp. http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf?ua=1 3. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis. 2010;4(8): e785. 4. Nguyen NM, Tran CNB, Phung LK, Duong KTH, Huynh HA, Farrar J, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013;207(9):1442–50. 5. Whitehorn J, Nguyen CVV, Khanh LP, Kien DTH, Quyen NTH, Tran NTT, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind placebo-controlled trial. Clin Infect Dis. 2016;62(4):468–76.
|
|